140 related articles for article (PubMed ID: 17824291)
1. Effects of different AT1-receptor antagonists in the therapy of severe heart failure pretreated with ACE inhibitors.
Gremmler B; Kisters K; Kunert M; Schleiting H; Ulbricht LJ
Acta Cardiol; 2007 Aug; 62(4):321-8. PubMed ID: 17824291
[TBL] [Abstract][Full Text] [Related]
2. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
Gremmler B; Kunert M; Schleiting H; Ulbricht LJ
Eur J Heart Fail; 2000 Jun; 2(2):183-7. PubMed ID: 10856732
[TBL] [Abstract][Full Text] [Related]
3. Effects of AT1 receptor antagonist therapy in patients with severe heart failure pretreated with angiotensin-converting enzyme inhibitors.
Gremmler B; Kunert M; Kisters K; Schleiting H; Ulbricht LJ
Exp Clin Cardiol; 2002; 7(4):193-8. PubMed ID: 19644591
[TBL] [Abstract][Full Text] [Related]
4. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
[TBL] [Abstract][Full Text] [Related]
8. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
9. Exploring new treatment strategies in heart failure.
Swedberg K
Blood Press Suppl; 2000; 1():44-8. PubMed ID: 11059637
[TBL] [Abstract][Full Text] [Related]
10. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study.
Derosa G; Ragonesi PD; Mugellini A; Ciccarelli L; Fogari R
Hypertens Res; 2004 Jul; 27(7):457-64. PubMed ID: 15302981
[TBL] [Abstract][Full Text] [Related]
11. [CHARM study--new strategy for the treatment of heart failure].
Hasegawa H; Komuro I
Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
[TBL] [Abstract][Full Text] [Related]
12. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
McMurray JJ; Ostergren J; Swedberg K; Granger CB; Held P; Michelson EL; Olofsson B; Yusuf S; Pfeffer MA;
Lancet; 2003 Sep; 362(9386):767-71. PubMed ID: 13678869
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
Fogari R; Zoppi A; Ferrari I; Mugellini A; Preti P; Lazzari P; Derosa G
Horm Metab Res; 2009 Dec; 41(12):893-8. PubMed ID: 19708000
[TBL] [Abstract][Full Text] [Related]
15. Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan.
de Denus S; Zakrzewski-Jakubiak M; Dubé MP; Bélanger F; Lepage S; Leblanc MH; Gossard D; Ducharme A; Racine N; Whittom L; Lavoie J; Touyz RM; Turgeon J; White M
Ann Pharmacother; 2008 Jul; 42(7):925-32. PubMed ID: 18594050
[TBL] [Abstract][Full Text] [Related]
16. [Angiotensin receptor blockers in heart failure. CHARM Study].
Kochsiek K
Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
[No Abstract] [Full Text] [Related]
17. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Zeller A; Battegay E
Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
[TBL] [Abstract][Full Text] [Related]
18. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Hennekens CH; Kowalczykowski M; Hollar D
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Kishi T; Hirooka Y; Konno S; Sunagawa K
J Hypertens; 2012 Aug; 30(8):1646-55. PubMed ID: 22728908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
